Cyclin-Dependent Kinase Modulators Studied at the NCI: Pre-Clinical and Clinical Studies

Title: Cyclin-Dependent Kinase Modulators Studied at the NCI: Pre-Clinical and Clinical Studies

Volume: 3 Issue: 1

Author(s): Edward A. Sausville

Affiliation:

Keywords: Cyclin-Dependent, Kinase Modulators, xenogaft, flavopiridol, glycoprotein

Abstract: The cyclin dependent kinases (CDKs) are key regulators of cell cycle progression. Lead compounds (from empirical anti-proliferative screening approaches) have been defined which modulate CDK function and have evidence of anti-proliferative activity in tissue culture systems and in some cases anti-tumor activity in vivo in conventional xenogaft models. Two of these, flavopiridol and UCN-01, have entered initial clinical testing. Flavopiridol is a “pan-CDK” inhibitor, with essentially equal potency in inhibiting all CDKs tested. The recent elucidation that in addition to cell cycle regulatory functions, CDK family members have been defined which regulate transcription, neuronal, and secretory function has increased the need for definition of CDK antagonists with greater selectivity. Novel purine, pyrimidine, and benzazepinone derivatives have been characterized in part

Cite this article as:

Sausville A. Edward, Cyclin-Dependent Kinase Modulators Studied at the NCI: Pre-Clinical and Clinical Studies, Current Medicinal Chemistry - Anti-Cancer Agents 2003; 3 (1) . https://dx.doi.org/10.2174/1568011033353560